57
Views
6
CrossRef citations to date
0
Altmetric
Letter to the Editor

Dasatinib restores full donor chimerism in a patient with imatinib-resistant Ph+ ALL relapsing after unrelated cord blood transplantation

, , , , , & show all
Pages 2054-2057 | Received 04 Jun 2007, Accepted 01 Jul 2007, Published online: 01 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Françoise Huguet. (2015) Dasatinib for acute lymphoblastic leukemia. Expert Opinion on Orphan Drugs 3:11, pages 1339-1356.
Read now
Takayoshi Tachibana, Ayumi Numata, Masatsugu Tanaka, Kenji Motohashi, Shin Fujisawa, Hiroyuki Fujita, Rika Sakai, Naoto Tomita, Atsuo Maruta, Yoshiaki Ishigatsubo & Heiwa Kanamori. (2011) Successful treatment with dasatinib and allogeneic peripheral blood stem cell transplant for imatinib-resistant Philadelphia chromosome-positive acute lymphoblastic leukemia relapsing after bone marrow transplant and donor lymphocyte infusion. Leukemia & Lymphoma 52:7, pages 1376-1379.
Read now

Articles from other publishers (4)

S. Giammarco, S. Bellesi, E. Metafuni, M. Rossi, G. Minnella, A. Bacigalupo, S. Sica & P. Chiusolo. (2022) Cord blood resilience in a patient with relapsing Ph + B lymphoblastic acute leukemia after hematopoietic stem cell transplantation. Annals of Hematology 101:11, pages 2565-2566.
Crossref
Muhammad Waqas Khan, Ahmed Elmaaz & Zartash Gul. 2018. Stem Cells in Clinical Practice and Tissue Engineering. Stem Cells in Clinical Practice and Tissue Engineering.
M Conchon, S S Sanabani, I Bendit, M Serpa, U A Filho, P de Barros Ferreira, M M Y Novaes, R Saboya, P E Llacer-Dorliac & F L Dulley. (2009) Achievement of complete donor-type chimerism and remission with dasatinib in Philadelphia chromosome-positive ALL relapsing after allogeneic transplantation. Bone Marrow Transplantation 45:6, pages 1125-1126.
Crossref
J L Liesveld & P G Rothberg. (2008) Mixed chimerism in SCT: conflict or peaceful coexistence?. Bone Marrow Transplantation 42:5, pages 297-310.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.